NEW YORK (GenomeWeb News) – The Institute of Cancer Research, London has granted Oxford Gene Technology a license to develop a panel of diagnostic and prognostic prostate cancer microRNA biomarkers into a new assay, OGT said today.

The license is the result of a three-year collaboration, under which ICR and OGT discovered new microRNA biomarkers with a range of applications for the diagnosis, prognosis, treatment planning, and monitoring of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.